市場調查報告書

中國的基因改造促濾泡素β市場分析

Investigation Report on China's Recombinant Follitropin Beta Market, 2019-2023

出版商 China Research and Intelligence 商品編碼 907271
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的基因改造促濾泡素β市場分析 Investigation Report on China's Recombinant Follitropin Beta Market, 2019-2023
出版日期: 2019年08月20日內容資訊: 英文 30 Pages
簡介

本報告提供中國國內的基因改造促濾泡素β市場相關分析,產品的概要、功效和授權情形,整體市場規模趨勢預測 (過去、今後5年份),市場價格的變化及預測,主要企業的簡介與市場佔有率等資訊彙整,為您概述為以下內容。

第1章 基因改造促濾泡素β的相關概念

  • 基因改造促濾泡素β的適應症
  • 中國的基因改造促濾泡素β市場發展
  • 中國國內的基因改造促濾泡素β的相關專利和政府核准趨勢

第2章 中國國內的基因改造促濾泡素β的銷售量

  • 基因改造促濾泡素β的銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 基因改造促濾泡素β的銷售量
    • 整體銷售量
    • 各地區的銷售量
  • 基因改造促濾泡素β的按銷售額:劑型 (過去5年份)

第3章 基因改造促濾泡素β的主要製造商分析

  • 主要廠商的市場佔有率分析
    • 以金額為準
    • 以數量為準
  • Organon
    • 企業簡介
    • 中國國內的基因改造促濾泡素β的銷售量

第4章 基因改造促濾泡素β國內價格

  • Organon (Puregon)
  • 基因改造促濾泡素β的價格趨勢

第5章 中國的基因改造促濾泡素β市場未來展望

  • 對市場的影響要素
    • 推動市場要素與市場機會
    • 威脅與課題
  • 市場規模的預測 (今後5年份)
  • 市場趨勢的預測 (今後5年份)
目錄
Product Code: 1908399

Description

In China, the number of infertile couples is increasing. According to Chinese media, in 2018, more than 40 million people in China were infertile, with the incidence of infertility in couples of childbearing age increasing from 3% 20 years ago to 15% in recent years. According to the Global Burden of Disease, in 2017, the incidence of infertility was 2,705.66/100,000 in Chinese women and 879.32/100,000 in Chinese men. The common causes of female infertility include ovulation disorders, fallopian tube damages and endometriosis; the major causes of male infertility include varicoceles, infections, ejaculation disorders and anti-sperm antibodies.

The increasing incidence of infertility in China is attributable to the endocrine disorders caused by worsening environmental pollution, increasing life pressures and unhealthy lifestyle, the increase in the average childbearing age of women, and the damages to female fertility caused by induced abortion.

Infertility is mainly treated by drug, surgery and assisted reproductive technology (ART). The drugs are ovulation stimulants that apply to the couples who have no organic disorders. Surgeries apply to organic disorders such as varicoceles in men and blocked fallopian tubes and intrauterine adhesion in women.

If drugs or surgeries do not work or if couples have other indications, ART will be applied. About 20% infertility patients are treated by ART. ART procedures mainly include artificial insemination (AI) and in vitro fertilization and embryo transfer (IVF-ET, or test-tube baby) and their derivative technologies. They bring higher pregnancy rate than drugs and surgeries. As the success rate of AI is lower, some patients directly choose IVF-ET. And some patients turn to IVF-ET after repeated AI failures. At the end of 2018, more than 450 medical institutions were qualified to implement ART, of which 350 could implement IVF-ET and more than 40 could provide pre-implantation genetic diagnosis; the number of ART practitioners reached 10,000; the clinical pregnancy rate of ART in China was 40% and the live birth rate was 30% to 35%. China have over 200,000 newborn test-tube babies every year, ranking the first in the world.

In 2006, the Recombinant Follitropin Beta injection by Merck Sharp & Dohme became the first Recombinant Follitropin Beta product approved to be sold in China. In 2011, Recombinant Follitropin Beta (trade name: Puregon) by Organon (now affiliated to Merck Sharp & Dohme) was approved to be sold in China. And all the Recombinant Follitropin Beta products on the Chinese market are the products of Organon. The sales value of Recombinant Follitropin Beta kept rising after the drug entered China. It reached about CNY 126 million in 2017.

In China, Recombinant Follitropin Beta is used to treat anovulation (including polycystic ovary disease, PCOD) that cannot be cured by clomiphene citrate. It is also used in ART procedures such as IVF-ET, gamete intrafallopian transfer (GIFT) and Intracytoplasmic sperm injection (ICSI) for controlled ovarian hyperstimulation and follicular development.

As the incidence of infertility increases, the demand for Recombinant Follitropin Beta in China will keep growing. From 2019 to 2023, China's Recombinant Follitropin Beta market will continue to expand. In the next few years, Recombinant Follitropin Beta products by enterprises other than Organon will possibly be launched in China.

Topics covered:

  • Incidence of infertility in China
  • Status of China's Recombinant Follitropin Beta market
  • Prices of Recombinant Follitropin Beta in China
  • Major factors influencing development of China's Recombinant Follitropin Beta market
  • Prospect of China's Recombinant Follitropin Beta market from 2019 to 2023

Table of Contents

1 Relevant Concepts of Recombinant Follitropin Beta

  • 1.1 Indications for Recombinant Follitropin Beta
  • 1.2 Development of Recombinant Follitropin Beta in China
  • 1.3 Patents and Government Approval on Recombinant Follitropin Beta in China

2 Sales of Recombinant Follitropin Beta in China, 2013-2017

  • 2.1 Sales Value of Recombinant Follitropin Beta
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Recombinant Follitropin Beta
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Recombinant Follitropin Beta by Dosage Form in China, 2013-2017

3 Analysis on Major Manufacturers of Recombinant Follitropin Beta in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Manufacturers of Recombinant Follitropin Beta
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Organon
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Recombinant Follitropin Beta by Organon in China

4 Prices of Recombinant Follitropin Beta in China, 2017-2018

  • 4.1 Organon (Puregon)
  • 4.2 Price Trend of Recombinant Follitropin Beta

5 Prospect of China's Recombinant Follitropin Beta Market, 2019-2023

  • 5.1 Factors Influencing Development of China's Recombinant Follitropin Beta Market
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Patents on Recombinant Follitropin Beta in China
  • Chart Government Approval on Recombinant Follitropin Beta in China
  • Chart Sales of Recombinant Follitropin Beta in China, 2013-2017
  • Chart Sales Value of Recombinant Follitropin Beta in Parts of China, 2013-2017
  • Chart Sales Volume of Recombinant Follitropin Beta in China, 2013-2017
  • Chart Sales Volume of Recombinant Follitropin Beta in Parts of China, 2013-2017
  • Chart Sales Value of Recombinant Follitropin Beta Injections in China, 2013-2017
  • Chart Sales Volume of Recombinant Follitropin Beta Injections in China, 2013-2017
  • Chart Sales Value of Recombinant Follitropin Beta by Organon in China, 2013-2017
  • Chart Sales Volume of Recombinant Follitropin Beta by Organon in China, 2013-2017
  • Chart Prices of Recombinant Follitropin Beta by Organon in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Recombinant Follitropin Beta in China, 2019-2023
Back to Top